Hypoparathyroidism Drug Profiles and Clinical Trials- Global Trends and Analysis Review, H2 2017

  • ID: 4426707
  • Report
  • Region: Global
  • 56 Pages
  • VPA Research
1 of 5

FEATURED COMPANIES

  • Amorphical Ltd.
  • Entera Bio Ltd.
  • NPS Pharmaceuticals, Inc.
  • Shire Plc
  • MORE

Hypoparathyroidism clinical trials report provides comprehensive analysis and trends in global Hypoparathyroidism disease clinical trials. The research work analyzes the evolution of Hypoparathyroidism clinical trial trends across countries and regions.

The report focuses on drugs and therapies being evaluated for Hypoparathyroidism treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, phases, trial status and sponsor types.

Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner offering quick access to Hypoparathyroidism clinical trials.

Major drugs under development in Hypoparathyroidism are provided in the report along with their details of Mechanism of Action, Route of Administration, Target, therapy, molecule and class.

Scope of the Report:

  • Number of Hypoparathyroidism clinical trials across regions- Asia and Oceania, Europe, Middle East Africa and Americas
  • Trial information by Phase and Subjects recruited
  • Trial information by status, type, sponsor type
  • Drugs used for treatment of Hypoparathyroidism
  • Both observational and interventional trials analyzed
  • Success rates of trials are analyzed
  • Trends in enrollment over the past ten years identified
  • Leading sponsors of Hypoparathyroidism clinical trials worldwide are listed

Reasons to Buy:

  • Track competition and design competitive advantages
  • Identify right partners to associate with for further research
  • Evaluate potential opportunities available in further clinical trials of the disease
  • Formulate business development strategies through success rates of clinical trials
  • Identify quick markets for recruiting subjects based on trials count by each market

Hypoparathyroidism is relatively rare form of thyroid disorders, expected to affect around 60,000 people in the US. The disease is caused when parathyroid glands fails to produce PTH (parathyroid hormone). The primary cause of failure of the parathyroid glands is often removal of parathyroid glands by surgery. Though rarely, family history, congenital diseases or auto-immune diseases can cause failure of the glands.

The disease is classified into two categories based on the cause of occurrence:

  • Iatrogenic Hypoparathyroidism- arising from known causes such as surgery
  • Idiopathic Hypoparathyroidism- unknown causes
  • Congenital (during birth)
  • Inheritance (family history)
  • Auto-immune (due to auto-antibodies)
  • Genetic

Failure to produce required levels of PTH leads to decline in calcium and phosphorous in patients. The condition is also generally associated with renal diseases, stones in kidneys, cataracts and calcification of soft tissues.

Key symptoms observed in Hypoparathyroidism glands include numbness, irregular heartbeats, cramps and seizures.

Drugs- Often Vitamin D analogue together with a Calcium supplement are administered to patients with Hypoparathyroidism.

READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amorphical Ltd.
  • Entera Bio Ltd.
  • NPS Pharmaceuticals, Inc.
  • Shire Plc
  • MORE

1 Table of Contents
1.1 List of Figures
1.2 List of Tables

2 Executive Summary
2.1 Report Guide
2.2 Key Findings
2.2.1 Overview of Global Clinical Trials Initiated in 2017
2.2.2 Average Enrolment by Country, 2010 - 2017
2.2.3 Prominent Companies in Global Hypoparathyroidism Trials, 2010 - 2017

3 Hypoparathyroidism Drugs in Ongoing and Completed Trials
3.1 Prominent Drugs in Development and Approved Stages for Hypoparathyroidism
3.2 Hypoparathyroidism Product Snapshots
3.2.1 Hypoparathyroidism Drug Profiles

4 Global Hypoparathyroidism Clinical Trial Research Trends
4.1 Clinical Trials by Top 10 Countries, 2010 - 2017
4.1.1 Clinical Trials by Country
4.1.2 Number of Ongoing/Planned Trial Locations in Each Country
4.2 Subjects Recruited by Top 10 Countries, 2010 - 2017
4.2.1 Total Enrolment by Country
4.3 Clinical Trials by Region, 2010 - 2017
4.4 Subjects Recruited by Region, 2010 - 2017
4.5 Clinical Trials by Year, 2010 - 2017
4.6 Subjects Recruited by Year, 2010 - 2017
4.7 Clinical Trials by Development Phase, 2010 - 2017
4.7.1 Clinical Trials by Phase
4.8 Subjects Recruited by Development Phase, 2010 - 2017
4.9 Clinical Trials by Status, 2010 - 2017
4.10 Subjects Recruited by Trial Status, 2010 - 2017
4.11 Clinical Trials by Sponsor Type, 2010 - 2017
4.12 Subjects Recruited by Sponsor Type, 2010 - 2017
4.13 Clinical Trials by Economy Type, 2010 - 2017
4.14 Clinical Trials and Subjects Recruited by Study Type, 2010 - 2017

5 Europe Hypoparathyroidism Clinical Trial Research Trends
5.1 Clinical Trials by Top Countries in Europe, 2010 - 2017
5.1.1 Europe, Clinical Trials by Country
5.2 Subjects Recruited by Top Countries in Europe, 2010 - 2017
5.2.1 Europe, Total Enrolment by Country
5.3 Europe, Clinical Trials by Year, 2010 - 2017
5.4 Europe, Clinical Trials by Development Phase, 2010 - 2017
5.5 Europe, Clinical Trials by Trial Status, 2010 - 2017
5.6 Europe, Clinical Trials by Sponsor Type, 2010 - 2017

6 Americas Hypoparathyroidism Clinical Trial Research Trends
6.1 Clinical Trials by Top Countries in Americas, 2010 - 2017
6.1.1 Americas, Clinical Trials by Country
6.2 Subjects Recruited by Top Countries in Americas, 2010 - 2017
6.2.1 Americas, Total Enrolment by Country
6.3 Americas, Clinical Trials by Year, 2010 - 2017
6.4 Americas, Clinical Trials by Development Phase, 2010 - 2017
6.5 Americas, Clinical Trials by Trial Status, 2010 - 2017
6.6 Americas, Clinical Trials by Sponsor Type, 2010 - 2017

7 Recent Clinical Trials - Snapshots
7.1 Hypoparathyroidism Trial Snapshots - 2017
7.2 Hypoparathyroidism Trial Snapshots - 2016
7.3 Hypoparathyroidism Trial Snapshots - 2015
7.4 Hypoparathyroidism Trial Snapshots - 2014
7.5 Hypoparathyroidism Trial Snapshots - 2013
7.6 Hypoparathyroidism Trial Snapshots - 2011

8 Appendix
8.1 About the Publisher
8.2 Sources and Research Methodology

List of Figures:
Figure 1: Hypoparathyroidism - Average Enrolment by Country, 2010 - 2017
Figure 2: Hypoparathyroidism - Country wise Clinical Trials, 2010 - 2017
Figure 3: Hypoparathyroidism - Country wise Recruiting Sites, 2010 - 2017
Figure 4: Hypoparathyroidism - Country wise Subjects Recruited, 2010 - 2017
Figure 5: Global Hypoparathyroidism Clinical Trials Participation Share by Region, 2010 - 2017
Figure 6: Global Hypoparathyroidism Subjects Recruited by Region, 2010 - 2017
Figure 7: Global Hypoparathyroidism Clinical Trials by Year, 2010 - 2017
Figure 8: Global Hypoparathyroidism Subjects Recruited by Year, 2010 - 2017
Figure 9: Global Hypoparathyroidism Trials by Phase, 2010 - 2017
Figure 10: Global Hypoparathyroidism - Subjects Recruited by Phase, 2010 - 2017
Figure 11: Global Hypoparathyroidism - Clinical Trials by Recruitment Status, 2010 - 2017
Figure 12: Global Hypoparathyroidism - Subjects Recruited by Trial Status, 2010 - 2017
Figure 13: Global Hypoparathyroidism - Clinical Trials by Sponsor Type, 2010 - 2017
Figure 14: Global Hypoparathyroidism - Subjects Recruited by Trial Status, 2010 - 2017
Figure 15: Global Hypoparathyroidism - Clinical Trials by Type of Economy, 2010 - 2017
Figure 16: Europe Hypoparathyroidism - Country wise Clinical Trials, 2010 - 2017
Figure 17: Europe Hypoparathyroidism - Country wise Subjects Recruited, 2010 - 2017
Figure 18: Europe Hypoparathyroidism - Year wise Clinical Trials, 2010 - 2017
Figure 19: Europe Hypoparathyroidism Trials by Phase, 2010 - 2017
Figure 20: Europe Hypoparathyroidism - Clinical Trials by Recruitment Status, 2010 - 2017
Figure 21: Europe Hypoparathyroidism - Clinical Trials by Sponsor Type, 2010 - 2017
Figure 22: Americas Hypoparathyroidism - Country wise Clinical Trials, 2010 - 2017
Figure 23: Americas Hypoparathyroidism - Country wise Subjects Recruited, 2010 - 2017
Figure 24: Americas Hypoparathyroidism - Year wise Clinical Trials, 2010 - 2017
Figure 25: Americas Hypoparathyroidism Trials by Phase, 2010 - 2017
Figure 26: Americas Hypoparathyroidism - Clinical Trials by Recruitment Status, 2010 - 2017
Figure 27: Americas Hypoparathyroidism - Clinical Trials by Sponsor Type, 2010 - 2017

List of Tables:
Table 1: Hypoparathyroidism Pipeline Drug Profiles - Type, Class, Route of Administration, Mechanism of Action, Target (1)
Table 2: Hypoparathyroidism - Region wise Clinical Trials, 2010 - 2017
Table 3: Hypoparathyroidism - Region wise Subjects Recruited, 2010 - 2017
Table 4: Global Hypoparathyroidism - Clinical Trials and Subjects by Trial Type, 2010 - 2017
Table 5: Hypoparathyroidism Trial Snapshots - 2017
Table 6: Hypoparathyroidism Trial Snapshots - 2017
Table 7: Hypoparathyroidism Trial Snapshots - 2017
Table 8: Hypoparathyroidism Trial Snapshots - 2016
Table 9: Hypoparathyroidism Trial Snapshots - 2016
Table 10: Hypoparathyroidism Trial Snapshots - 2016
Table 11: Hypoparathyroidism Trial Snapshots - 2016
Table 12: Hypoparathyroidism Trial Snapshots - 2015
Table 13: Hypoparathyroidism Trial Snapshots - 2014
Table 14: Hypoparathyroidism Trial Snapshots - 2013
Table 15: Hypoparathyroidism Trial Snapshots - 2013
Table 16: Hypoparathyroidism Trial Snapshots - 2011
Table 17: Hypoparathyroidism Trial Snapshots - 2011
Table 18: Hypoparathyroidism Trial Snapshots - 2011

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Amorphical Ltd.
  • Entera Bio Ltd.
  • NPS Pharmaceuticals, Inc.
  • Shire Plc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll